#1 Clinical Trials Search in Europe

Brinzolamide

Brinzolamide, a carbonic anhydrase inhibitor, has been the subject of several clinical trials investigating its efficacy in treating various eye conditions, primarily glaucoma and ocular hypertension. These studies aim to evaluate the drug’s effectiveness in reducing intraocular pressure (IOP) and compare it to other established treatments. The trials also explore different formulations and combinations of brinzolamide with other medications to optimize patient outcomes.

Table of Contents

What is Brinzolamide?

Brinzolamide is a medication used in ophthalmology, primarily for treating eye conditions related to increased pressure within the eye. It belongs to a class of drugs called carbonic anhydrase inhibitors[1]. Brinzolamide is often marketed under the brand name Azopt[2], which is a 1% ophthalmic suspension (eye drops) containing brinzolamide as the active ingredient.

Conditions Treated by Brinzolamide

Brinzolamide is primarily used to treat the following eye conditions:

  • Open-Angle Glaucoma: This is a type of glaucoma where the drainage channels in the eye become gradually clogged over time, leading to increased eye pressure[2][3].
  • Ocular Hypertension: This condition is characterized by higher than normal pressure inside the eye, without any detectable changes in vision or damage to the eye structure[2][3].
  • Central Serous Chorioretinopathy: This is an eye condition where fluid builds up under the retina, causing a small detachment and distortion of vision. Brinzolamide is being studied as a potential treatment for this condition[1].

How Brinzolamide Works

Brinzolamide works by reducing the production of fluid inside the eye, known as aqueous humor. It does this by inhibiting an enzyme called carbonic anhydrase. By decreasing fluid production, brinzolamide helps lower the pressure inside the eye, which is beneficial in conditions like glaucoma and ocular hypertension[1].

How Brinzolamide is Administered

Brinzolamide is typically administered as eye drops. The usual dosage is one drop in the affected eye(s) three times daily[2]. However, the exact dosage may vary depending on the specific condition being treated and the doctor’s recommendations. It’s important to follow your eye doctor’s instructions carefully when using this medication.

Efficacy of Brinzolamide

Several clinical trials have demonstrated the effectiveness of brinzolamide in lowering intraocular pressure (IOP). For instance:

  • A study compared brinzolamide to latanoprost (another eye pressure-lowering medication) in treating open-angle glaucoma and ocular hypertension. Both medications were found to be effective in reducing IOP[3].
  • Another study evaluated the efficacy of brinzolamide when added to other glaucoma medications, showing that it can provide additional IOP-lowering effects when used as an adjunctive therapy[4].

Combination Therapies with Brinzolamide

Brinzolamide is often used in combination with other eye medications to enhance its IOP-lowering effect. Some examples include:

  • Brinzolamide/Brimonidine: This fixed-dose combination has been studied for preventing IOP elevation after intravitreal injections[5].
  • Brinzolamide/Timolol: This combination has been investigated for treating open-angle glaucoma or ocular hypertension[6].
  • Travoprost/Brinzolamide: This combination has been studied for its IOP-lowering efficacy in patients with open-angle glaucoma or ocular hypertension[7].

Other Potential Uses of Brinzolamide

Researchers are exploring the potential of brinzolamide for treating other eye conditions. For example, a study is investigating its use in treating chronic central serous chorioretinopathy, a condition where fluid accumulates under the retina[1]. This research may expand the applications of brinzolamide in the future.

Side Effects and Considerations

While brinzolamide is generally well-tolerated, it may cause some side effects. Common side effects can include blurred vision, eye discomfort, or a bitter taste in the mouth. It’s important to discuss any side effects with your eye doctor. Additionally, brinzolamide may not be suitable for everyone, so it’s crucial to inform your doctor about your medical history and any other medications you’re taking before starting treatment with brinzolamide[6].

Aspect Details
Primary Conditions Studied Open-angle glaucoma, Ocular hypertension
Secondary Conditions Central serous chorioretinopathy
Main Outcome Measure Reduction in intraocular pressure (IOP)
Dosage Forms Ophthalmic suspension (eye drops)
Dosing Frequency Once to three times daily
Comparison Treatments Timolol, Latanoprost, Dorzolamide
Combination Therapies Brinzolamide/Timolol, Brinzolamide/Travoprost
Study Designs Randomized controlled trials, Bioequivalence studies
Treatment Duration 2 to 16 weeks
Secondary Outcomes Visual acuity, Retinal thickness, Patient comfort

FAQ

  • What is brinzolamide and how does it work? Brinzolamide is a carbonic anhydrase inhibitor used to treat glaucoma and ocular hypertension. It works by reducing the production of fluid in the eye, which helps lower intraocular pressure.
  • What conditions are being studied in these clinical trials? The clinical trials are primarily focused on open-angle glaucoma and ocular hypertension. Some studies also investigate its use in central serous chorioretinopathy.
  • How is brinzolamide administered in these trials? Brinzolamide is typically administered as an ophthalmic suspension (eye drops). In most trials, it is applied topically to the eye, with dosing frequencies ranging from once to three times daily.
  • What are the main outcomes measured in these clinical trials? The primary outcome in most trials is the reduction in intraocular pressure (IOP). Other outcomes include visual acuity, changes in retinal and choroidal thickness, and patient comfort or quality of life.
  • Are there any combination therapies being studied with brinzolamide? Yes, several trials are investigating combination therapies. These include fixed combinations of brinzolamide with other drugs such as travoprost and timolol, as well as its use as an adjunctive therapy to prostaglandin analogues.

Ongoing Clinical Trials on Brinzolamide

  • Study on the Safety and Effectiveness of AGTC-501 for Men with X-linked Retinitis Pigmentosa

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Glaucoma Treatment: Comparing Brimonidine, Pilocarpine Nitrate, and Brinzolamide in Patients with Newly Diagnosed Open-Angle Glaucoma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Sweden

  • Study Comparing Brinzolamide and Timolol Eye Drops for Patients with Glaucoma or Ocular Hypertension

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Greece

Glossary

  • Intraocular Pressure (IOP): The fluid pressure inside the eye. Elevated IOP is a major risk factor for glaucoma and is the primary target for glaucoma treatments.
  • Open-Angle Glaucoma: A type of glaucoma where the angle between the iris and cornea is open, but the eye's drainage canals become clogged over time, leading to increased intraocular pressure.
  • Ocular Hypertension: A condition where the pressure inside the eye (intraocular pressure) is higher than normal, but without detectable changes in vision or damage to the eye structure.
  • Carbonic Anhydrase Inhibitor: A class of medications that work by decreasing the production of fluid inside the eye, thereby lowering intraocular pressure.
  • Prostaglandin Analogue (PGA): A type of medication used to treat glaucoma by increasing the outflow of fluid from the eye, thus lowering intraocular pressure.
  • Central Serous Chorioretinopathy: An eye condition that causes fluid buildup under the retina, leading to vision distortion and potential vision loss.
  • Ophthalmic Suspension: A liquid medication for the eye where the active ingredient is suspended in a liquid medium, typically used as eye drops.
  • Adjunctive Therapy: An additional treatment used together with the primary treatment to increase its effectiveness.
  • Fixed Combination: A medication that combines two or more active ingredients in a single formulation, often used to simplify treatment regimens.
  • Bioequivalence: The absence of a significant difference in the rate and extent at which the active ingredient in pharmaceutical equivalents becomes available at the site of action when administered at the same dose under similar conditions.

References

  1. https://clinicaltrials.gov/study/NCT03542006
  2. https://clinicaltrials.gov/study/NCT03896633
  3. https://clinicaltrials.gov/study/NCT01084902
  4. https://clinicaltrials.gov/study/NCT00300079
  5. https://clinicaltrials.gov/study/NCT04523844
  6. https://clinicaltrials.gov/study/NCT00326092
  7. https://clinicaltrials.gov/study/NCT00527501